Background BRAF mutations have been well described in non-small cell lung cancer (NSCLC) for several years, but the clinical features of patients harboring BRAF mutations are still not well described.
The study incorporated RNA-sequencing (RNA-seq) and whole-exome sequencing (WES) data from 38 patients with non-small cell lung cancer (NSCLC), along with relevant clinical data.
